Skip to main content

Partnerships to accelerate development and bring innovative therapies to patients faster

Tackling some of the most widespread and underserved conditions in medicine

At Topadur, we are addressing urgent and global health challenges impacting over 1.7 billion people. Existing therapies often fail to address a key factor of vascular and age-related diseases, resulting in limited, outdated, or invasive treatment options with low success rates and systemic side effects – leaving a clear need for safer, more effective, and locally active solutions.

Addressing a USD 2.9 billion (2021) global systemic sclerosis (scleroderma) market, with an estimated 1.47 million people affected worldwide, TOP-N53 is among the first therapies in clinical development for digital ulcers in systemic sclerosis – offering a first-in-class approach in a true therapeutic white space. Following a successful Phase 1 trial that met all safety, tolerability, and exploratory efficacy endpoints, TOP-N53 is now in phase 2a, backed by EMA Orphan Drug Designation – positioning it for accelerated access and extended exclusivity.

Diabetic foot ulcers (DFUs) affect approximately 18.6 million people worldwide each year, representing a USD 8.2 billion (2021) global market, currently dominated by device-based treatments. Delivered topically TOP-N53 has shown unprecedented efficacy, safety, and tolerability in preclinical models, highlighting its potential to address a major unmet need in this high-burden condition.

Androgenetic alopecia therapy accounts for a USD 8.8 billion (2023) market around the world, affecting 535 million people. TOP-M119 offers one of the first non-hormonal topically administered treatments in development, with preclinical data indicating superior efficacy and a favorable safety profile compared to existing therapies. Topadur has entered a development and licensing partnership with Oshen Holdings SA to advance this asset into Phase 2 clinical development in the Greater China region.

    Explore Our Pipeline & What Sets us Apart

    A capital-efficient partnership-driven model for successful innovation

    By employing a network-based R&D model, we both accelerate innovation and reduce risk to bring therapies to patients faster. Our team of experts in Switzerland drive key R&D functions, while collaborations with top-tier CROs and academic centers around the world give us access to latest disease models and respected key opinion leaders and keeps the company at the forefront of medical innovation. Over the past years, we are proud to have built a strong network of international collaborations with globally recognized partners.

    For commercialization and development in international markets, we welcome collaborations through co-development alliances, regional licensing deals, and strategic investment. Together, we are building a robust, innovation-driven company creating enduring value for patients, partners, and investors alike.

    About us

    An attractive investment opportunity

    Guided by former Novartis leadership and senior biotech executives, Topadur advances a strong first-in-class pipeline targeting high-impact vascular and age-related disorders, offering investors a promising opportunity, strategically focused on sustainable growth.

    Our award-winning approach has earned recognition from leading European biotech initiatives and was supported through competitive public and private funding, including grants from organizations such as the Swiss Innovation Agency Innosuisse.

    Why partner with Topadur

    We offer collaborations to support the advancement of our innovative pipeline assets. These are first-in-class, de-risked, and backed by strong IP – offering significant potential in underserved high-growth markets, with clear development paths and go-to-market strategies. We currently focus on global or regional development & commercialization partnerships with established pharmaceutical companies for our lead candidate for systemic sclerosis and diabetic foot ulcers. For our alopecia asset, we are targeting such partnerships in select territories. In parallel, we continue to strengthen our scientific foundation through targeted R&D collaborations that support long-term pipeline growth.

    Contact us to find out more

    Unique strengths and opportunities

    First-in-class pipeline:

    De-risked assets with strong preclinical data, first human proof-of-concept & long IP runway.

    Built for sustained impact:

    Our platform drives a diversified pipeline with multiple avenues for success and a steady flow of future product candidates.

    Validated platform technology:

    Dual-acting therapies designed to restore microcirculation and resolve underlying disease drivers.

    Agile R&D partnering model:

    Combining proven in-house leadership with a global academic network unlocking access to breakthrough medical innovation and globally respected KOLs.